Doceree appoints global CTO to accelerate programmatic innovation in pharma marketing
The data science leader joins to drive adoption of programmatic solutions in the lifesciences industry as Doceree steps into next phase of growth post Series A funding
Doceree yesterday appointed Anil Dobhal as global Chief Technology Officer (CTO), who will lead the comapny’s global technology and product teams spanning the US, Europe and those in the emerging markets, a company statement notified.
“Pharma marketing is going through transformational times with hybrid approaches taking centerstage for most business. …….We are focussed on empowering our clients and partners with high-end technology solutions led by Artificial Intelligence (AI) and Machine Learning (ML). Anil’s deep expertise in programmatic design will help us utilise humungous data to churn valuable insights for our partners world over, enabling them to make key business decisions and optimise business outcomes in a very secure and transparent manner,” said Harshit Jain MD, Founder and Global CEO, Doceree, in the statement.
The company, which raised Series A funding of $11 million from reputed global investors, including Eight Roads Ventures, plans to create world-leading programmatic solutions in the space of pharma marketing, according to the statement.
“……..My key focus will be on automating the programmatic ecosystem with AI, ML and data science algorithms that optimise marketing initiatives of pharma and lifesciences companies and ensures better RPMs (ad revenue per thousand impressions) for publishers,” Dobhal noted in the statement.
A start-up and ad-tech enthusiast, Dobhal has extensive knowledge into fraud systems. In his past roles, he built scalable data security systems that dealt with huge volume. Prior to joining Doceree, he defined, implemented and commercialised solutions across different industries, including at One97 Communications and GlobalLogic, evolving solutions around Large Scale Databases, BI Stacks, and Big Data Platforms, among others, the statement concluded.